"The US Food and Drug Administration (FDA) has approved adalimumab (Humira, AbbVie) for use in patients with noninfectious intermediate and posterior uveitis and panuveitis, the company announced.
Adalimumab is the first and o"...
Doses of Macugen up to 10 times the recommended dosage of 0.3 mg have been studied. No additional adverse events have been noted but there is decreased efficacy with doses above 1 mg.
Ocular or Periocular Infections
Macugen is contraindicated in patients with ocular or periocular infections.
Macugen is contraindicated in patients with known hypersensitivity to pegaptanib sodium or any other excipient in this product.This monograph has been modified to include the generic and brand name in many instances.
Last reviewed on RxList: 2/6/2017
Additional Macugen Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get breaking medical news.